Mount Sinai and SOPHiA GENETICS Collaborate for Enhanced Cancer Precision Healthcare

Advancing Cancer Care: Mount Sinai and SOPHiA GENETICS Collaboration

In a significant leap forward for precision oncology, SOPHiA GENETICS (NASDAQ: SOPH), a leader in AI-driven healthcare solutions, announced a collaboration with the Mount Sinai Health System. This partnership aims to enhance cancer research and genomic testing capabilities using the innovative SOPHiA DDM™ Platform.

Mount Sinai, recognized as a National Cancer Institute-designated Comprehensive Cancer Center, is committed to providing top-notch care to over 4,000 oncology patients annually. By integrating the state-of-the-art SOPHiA DDM™ Platform into their operations, the institution will boost its capabilities in next-generation sequencing (NGS) for a variety of cancers, including blood cancers and solid tumors.

The advanced SOPHiA DDM™ Platform is designed to detect and interpret a broad spectrum of complex genomic variants. One of its key strengths lies in optimizing operational efficiency by consolidating vital steps in the data analysis pipeline, significantly reducing manual time required for interpretation. This progression towards enhanced efficiency will allow medical teams to prioritize direct patient care, ultimately leading to better patient outcomes.

Dr. Jane Houldsworth, the Director of Molecular Oncology Pathology at Mount Sinai, expressed enthusiasm about this collaboration, stating, “The integration of cutting-edge digital tools into our workflows represents our dedication to innovation in science and healthcare. The SOPHiA DDM™ Platform has significantly reduced our analysis times, enabling us to expedite testing while continuing to provide the highest quality of care to our patients.”

Similarly, John Carey, Managing Director at SOPHiA GENETICS for North America, emphasized the power of this partnership, noting, “Mount Sinai is globally recognized for its leadership in both cancer research and data-driven innovation. Its recent ranking as the number one healthcare institution in the Nature AI Index highlights its commitment to advancing healthcare through technology. We are thrilled to provide support through our AI-native platform and extensive global network which will enable faster results and increased understanding of genomic data.”

Using specific applications of the SOPHiA DDM™ for blood cancers and solid tumors, Mount Sinai is joining a global network of over 990 institutions that are harnessing SOPHiA GENETICS' decentralized platform to push the boundaries of precision medicine. This strategic alliance underscores SOPHiA GENETICS' mission to democratize data-driven medicine, making advanced genomic testing more accessible and improving health outcomes worldwide.

The announcement of this collaboration was made during the American Association for Cancer Research® (AACR) Annual Meeting held in San Diego. Attendees can learn more about this innovative partnership by visiting SOPHiA GENETICS at their booth (#4248) from April 17-22, 2026.

For further details on SOPHiA GENETICS, including their mission and ongoing projects, please visit SOPHiAGENETICS.com or connect on LinkedIn.

It is crucial to mention that SOPHiA GENETICS products are intended for research use only and are not certified for diagnostic procedures unless specified. Mount Sinai's clinical use of the SOPHiA DDM™ platform is managed independently and conducted within its accredited laboratory, adhering to necessary regulations. While promising, forward-looking statements made by the company are subject to market conditions and uncertainties, and accordingly, actual results may differ from those anticipated.

This collaboration signals a monumental shift in how data-driven precision medicine can evolve to improve the oncology landscape, making substantial strides in patient care and treatment efficacy. With technology like the SOPHiA DDM™, the future of cancer research and care looks more promising than ever.